Efficacy of artesunate-amodiaquine and artemether-lumefantrine for uncomplicated \textit{Plasmodium falciparum} malaria in Madagascar, 2018

Catherine M. Dentinger$^{1,2}$*, Tovonahary Angelo Rakotomanga$^{3,4}$, Antsa Rakotondrandriana$^{3}$, Arinomenjanahary Rakotoarisoa$^{3}$, Marie Ange Rason$^{3}$, Leah F. Moriarty$^{1,5}$, Laura C. Steinhardt$^{1}$, Laurent Kapesa$^{6}$, Jocelyn Razafindrakoto$^{6}$, Samaly S. Svigel$^{1}$, Naomi W. Lucchi$^{1}$, Venkatachalam Udhayakumar$^{1}$, Eric S. Halsey$^{1,5}$ and C. Arsène Ratsimbasa$^{3,7,8}$

Abstract

\textbf{Background:} Since 2005, artemisinin-based combination therapy (ACT) has been recommended to treat uncomplicated falciparum malaria in Madagascar. Artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first- and second-line treatments, respectively. A therapeutic efficacy study was conducted to assess ACT efficacy and molecular markers of anti-malarial resistance.

\textbf{Methods:} Children aged six months to 14 years with uncomplicated falciparum malaria and a parasitaemia of 1000–100,000 parasites/µl determined by microscopy were enrolled from May–September 2018 in a 28-day in vivo trial using the 2009 World Health Organization protocol for monitoring anti-malarial efficacy. Participants from two communes, Ankazomborona (tropical, northwest) and Matanga (equatorial, southeast), were randomly assigned to ASAQ or AL arms at their respective sites. PCR correction was achieved by genotyping seven neutral microsatellites in paired pre- and post-treatment samples. Genotyping assays for molecular markers of resistance in the \textit{pfk13}, \textit{pfcrt} and \textit{pfmdr1} genes were conducted.

\textbf{Results:} Of 344 patients enrolled, 167/172 (97%) receiving ASAQ and 168/172 (98%) receiving AL completed the study. For ASAQ, the day-28 cumulative PCR-uncorrected efficacy was 100\% (95\% CI 100–100) and 95\% (95\% CI 91–100) for Ankazomborona and Matanga, respectively; for AL, it was 99\% (95\% CI 97–100) in Ankazomborona and 83\% (95\% CI 76–92) in Matanga. The day-28 cumulative PCR-corrected efficacy for ASAQ was 100\% (95\% CI 100–100) and 98\% (95\% CI 95–100) for Ankazomborona and Matanga, respectively; for AL, it was 100\% (95\% CI 99–100) in Ankazomborona and 95\% (95\% CI 91–100) in Matanga. Of 83 successfully sequenced samples for \textit{pfk13}, no mutation associated with artemisinin resistance was observed. A majority of successfully sequenced samples for \textit{pfmdr1} carried either the NFD or NYD haplotypes corresponding to codons 86, 184 and 1246. Of 82 successfully sequenced samples for \textit{pfcrt}, all were wild type at codons 72–76.
Conclusion: PCR-corrected analysis indicated that ASAQ and AL have therapeutic efficacies above the 90% WHO acceptable cut-off. No genetic evidence of resistance to artemisinin was observed, which is consistent with the clinical outcome data. However, the most common pfmdr1 haplotypes were NYD and NFD, previously associated with tolerance to lumefantrine.

Keywords: Madagascar, Anti-malarial, Artemisinin-based combination therapy, Resistance, Efficacy

Background
Malaria remains a public health problem in Madagascar, an Indian Ocean island-nation with a population of 25.6 million [1]. In 2019, malaria was the fourth leading cause of death, and over one million cases of disease were reported nationally [2]. Although malaria is endemic throughout the country, prevalence is heterogeneous; rates of disease are lowest in the central highlands and highest along the east and west coasts of the island. According to routine public health surveillance data, this heterogeneity has increased in recent years, with some areas advancing toward malaria elimination and others experiencing upsurges and focal outbreaks of disease. Since 2005, the National Malaria Control Programme (NMCP) has recommended artemisinin-based combination therapy (ACT) for treatment of confirmed uncomplicated falciparum malaria [3]. In Madagascar, artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are the first- and second-line treatment recommendations, respectively.

Resistance to artemisinin-based drugs has been reported in Asia [4–6], and the threat of resistance to these drugs in Madagascar is of concern. Evidence of partial resistance to artemisinin compounds was recently reported in sub-Saharan Africa (SSA), amplifying these concerns [7].

The World Health Organization (WHO) recommends that malaria control programmes conduct periodic studies to monitor the therapeutic efficacy of recommended anti-malarials and to identify early emergence of resistance markers [8]. The most recent therapeutic efficacy study (TES) was conducted in 2016 in two Madagascar districts, Ifanadiana and Maevatanana, to monitor ASAQ. Results indicated that ASAQ had acceptable clinical efficacy with a 100% (95% CI 97–100) polymerase chain reaction (PCR)-corrected day-28 cure rate at both study sites [9]. For AL, however, no recent studies to evaluate therapeutic efficacy have been done in Madagascar. Evidence of reduced AL efficacy has been described in SSA [10–12]; given that it is the second-line anti-malarial in Madagascar, and has at times been used as the first-line treatment due to shortages of ASAQ, describing its efficacy in Madagascar is important.

In accordance with WHO recommendations for anti-malarial drug monitoring, the NMCP and partners conducted a TES in 2018 to evaluate the efficacy of the first- and second-line anti-malarials. In addition, Plasmodium falciparum parasite specimens were tested for the presence of molecular markers associated with resistance or reduced susceptibility to artesinin, amodiaquine and lumefantrine [13–17]. The results of this TES are described in this paper and the implications of the findings are discussed.

Methods
Study setting and design
An in vivo open-label study to test the efficacy and tolerance of ASAQ and AL for treatment of laboratory-confirmed uncomplicated falciparum malaria among Malagasy children was based on the standard WHO protocol [8]. Cases were recruited during May–September 2018 in two basic health centres (Centre de Santé de Base (CSB)) serving the communes of Ankazomborona, in Marovoay District in the northwest, and Matanga, in Vangaindrano District in the southeast (Fig. 1). These CSBs were selected to represent different climatic zones of the country; Ankazomborona is in the tropical zone and Matanga is in the equatorial zone. Both communes are in districts with moderate malaria transmission, defined as 50–100 cases per 1000 population per year [3]; in 2016, malaria parasite prevalence by microscopy among children 6–59 months of age was 9.0 and 8.8% in the zones encompassing Ankazomborona and Matanga, respectively [18]. Children in each site were randomly assigned to receive either ASAQ (Winthrop® Aventis, France) or AL (Coartem®, Novartis, Basel, Switzerland) and treated according to WHO/NMCP recommendations. To ensure study quality, staff from the US President’s Malaria Initiative (PMI) and the NMCP visited each site to observe study procedures and data management and provide feedback and support.

Primary and secondary endpoints and sample size
The primary endpoints were 28-day uncorrected and PCR-corrected efficacy. Sample size calculations were based on 28-day PCR-corrected efficacy and powered assuming a 5% failure rate with a 5% margin of error and 95% confidence level. Assuming loss to follow-up of 15%, a minimum of 86 patients per arm was needed at each site, for a total of 344 patients across the two sites.
Secondary endpoints included early treatment failures, day-3 parasite clearance, late clinical and parasitological failures, and the presence of single nucleotide polymorphisms (SNPs) associated with anti-malarial resistance or decreased response in the pfk13, pfmdr-1 and pfcrt genes.

Study population and participant enrolment
All children aged six months to 14 years presenting to the CSB for evaluation of febrile illness were referred to the TES team, who explained the study to parents. A rapid diagnostic test (RDT) (SD Bioline Malaria Ag Pf/Pan, Standard Diagnostics, Inc.) was administered according to the manufacturer’s instructions to diagnose malaria, and thick and thin smears for microscopy were prepared. All children with a positive RDT for P. falciparum, that was confirmed by microscopy to be P. falciparum mono-infection with a density of 1000–100,000 parasites/µl of blood, were invited to participate. Children with a negative RDT, and those without parental consent or assent (for those aged 7 to 14 years), were referred to the CSB clinician for care. After consent, a questionnaire was administered to eligible children or parents to collect demographic and clinical information and a physical examination was performed by the study physician. Pregnancy and lactation were assessed for all females ≥12 years of age; for those who had attained menarche and missed a menstrual period, a pregnancy test was done. Pregnant or lactating females were excluded and referred to the CSB clinician. A second finger stick was done to measure haemoglobin concentration (Hemocue®; HB 201+, Angelholm, Sweden); children with haemoglobin concentration <8 g/dl were excluded and referred to the CSB clinician. Capillary blood for dried blood spots (DBS) was also collected on Whatman 903 filter papers (GE Healthcare Life Sciences, PA, USA) during enrolment and used for molecular analyses. Additional criteria for enrolment included weight ≥5 kg, ability to take oral medication, and plans to remain in the study area for the following 28 days. Exclusion criteria included: signs of severe disease (i.e., prostration, change in mental status, convulsions, respiratory distress, persistent vomiting, haemoglobinuria, jaundice, haemorrhagic shock); underlying chronic illness or signs of severe malnutrition; reported allergy to one of the ACT; having taken an anti-malarial medication within the previous 30 days; having taken a medication which could interfere with one of the study medications; participation in another clinical study; and, residence >15 km from the CSB. Enrolled children were randomly assigned to treatment with either AL or ASAQ using block randomization, by age group (6–59 months, 5–9 years, 10–14 years), and a one-to-one ratio for the two medications. Once a child was enrolled, study staff selected the top envelope for that child's age group, which held the treatment indication.

Participant treatment, monitoring and follow-up
Children were treated by study personnel with a full course of either ASAQ or AL (tablets were crushed with water as needed) on days 0, 1 and 2 according to WHO/NMCP recommendations. For ASAQ, the following doses were administered based on the child's weight: 5 to <9 kg, 25 mg artemunate +67.5 mg amodiaquine base; 9 to <18 kg, 50 mg artemunate +135 mg amodiaquine base; 18 to <36 kg, 100 mg artemunate +270 mg amodiaquine
base; \( \geq 36 \text{ kg} \), 200 mg artesunate + 540 mg amodiaquine base. For AL, a first dose was given at time 0 followed by a second dose 8 h later; on days 2 and 3, the child was treated twice per day. Medication dose was based on the child’s weight: 5–15 kg, 20 mg artemether + 120 mg lumefantrine; 15 to < 25 kg, 40 mg artemether + 240 mg lumefantrine; 25 to < 35 kg, 60 mg artemether + 360 mg lumefantrine; \( \geq 35 \text{ kg} \), 80 mg artemether + 480 mg lumefantrine. All doses of medication, including the evening dose of AL, were administered with water only and were directly observed and monitored by study team personnel. Clinical and parasitological response to treatment and screening for adverse drug events occurred on days 1, 2, 3, 7, 14, 21, and 28; parents were instructed to bring their child to the health centre if symptoms occurred between scheduled visits. Blood samples, for microscopy and preparation of DBS, were collected from a finger stick at every visit, including unscheduled visits. Participants were withdrawn from the study and referred for care if they developed signs of severe disease or if an adverse event required discontinuing study treatment.

Study participants were classified as early treatment failures in the following situations: signs of severe malaria in the presence of parasitaemia up to day-3; day-2 parasitaemia higher than at day-0; day-3 parasitaemia above 25% of day-0 parasitaemia in the absence of fever; parasitaemia detected on day-3 in the presence of fever. Participants were classified as late treatment failures if they had not demonstrated early treatment failure and had at least one blood slide positive for asexual \( P. falciparum \) parasites after day-3. Patients negative for malaria on day-28 and not having previously met any treatment failure criteria, were classified as adequate clinical and parasitological response (ACPR). Participants with early or late treatment failure were discontinued and referred for care.

**Microscopy**

Microscopy slides were prepared at the study sites according to WHO guidelines; the first slide was prepared by staining with 10% Giemsa for 10–15 min to confirm the diagnosis and facilitate treatment. All slides were read on site by WHO certified level 1 or 2 microscopists to confirm mono-infection and calculate parasite density. Parasite density, expressed as the number of asexual parasites per µl of blood, was calculated by dividing the number of asexual parasites by the number of white blood cells and then multiplying by an assumed white blood cell density of 8000 per by study personnel. Slides were considered negative if no parasites were seen after examination of 200 oil-immersion fields in a thick blood film. Slides were read by two microscopists; for parasite density, the mean of the two readers was reported. Discrepant results (\( > = 25\% \)) were resolved by a third certified reader. For parasite density discrepancies \( \geq 25\% \), the mean value across all three readers was reported. To ensure microscopy quality, 20% of slides were randomly selected for re-reading after the study by WHO-certified NMCP microscopists, who were blinded to the original result.

**DNA extraction and molecular analysis**

Collected DBS were transported to the NMCP malaria reference laboratory in Antananarivo, the capital of Madagascar, where parasite DNA was extracted from DBS with QIAamp 96 DNA Blood kit (No. 51306) according to the manufacturer’s instructions (Quiagen Inc., Hilden, Germany).

Molecular analyses were performed on the Madagascar specimens by Madagascar laboratorians at the US Centers for Disease Control and Prevention Malaria Laboratory in Atlanta, GA, as part of the technical training objective of the PMI-sponsored Antimalarial Resistance Monitoring in Africa (PARMA) network [19]. Investigation of polymorphisms in codons 389–638 of the \( pfk13 \) propeller domain, codons 86, 184, 1034, 1042, and 1246 of \( pfmdr1 \), and codons 72–76 of \( pfert \) were done using Sanger sequencing [20] on 85 day-0 and 18 day-of-recurrence-para-sitaemia samples. The analysis of SNPs was done using the Geneious software package (Biomatters Inc., San Francisco, CA, USA) utilizing the 3D7 \( pfk13 \) (PF3D7_1343700), \( pfmdr1 \) (PF3D7_0523000) and \( pfert \) sequences (PF3D7_0709000) as references. Raw sequence reads were cleaned using default settings and reads with high-quality scores (\( > 30\% \)) were further analysed.

**Differentiation between recrudescence and re-infection**

PCR correction, to differentiate recrudescence from re-infection in those with a late treatment failure, was achieved by comparing seven neutral microsatellite genotypes (TA1 on chromosome 6, Poly-\( \alpha \) on chromosome 4, PPK2 on chromosome 12, 2490 on chromosome 10, C2M34-313 on chromosome 2, C2M69-383 on chromosome 3, and TA109 on chromosome 6) in the paired pre-treatment and post-treatment samples using previously described methods [21, 22]. The sizes of the amplification products were determined by capillary electrophoresis on an Applied Biosystems 3130 xl sequencer (Applied Biosystems, Foster City, CA, USA). A previously validated Bayesian algorithm was used to generate a posterior probability of recrudescence for each late treatment failure [23].

**Statistical analysis**

Data were recorded in the field into WHO-standard templates [24] and later double-entered into an Excel database at the NMCP’s reference laboratory. Statistical
analyses were performed using R version 4.0.1 (R Foundation for Statistical Computing, Vienna, Austria).

Uncorrected and PCR-corrected per protocol efficacy for each site and drug was calculated by dividing the number of participants classified as ACPR over all participants reaching a study outcome. The sum of posterior probabilities of recrudescence was used to calculate the total number of recrudescent infections for the PCR-corrected analyses. Re-infections were removed from the calculations of PCR-corrected per protocol efficacy. For Kaplan–Meier cumulative efficacy estimates, re-infections were removed (censored) on the day of re-infection and participants lost to follow-up or who withdrew were included until the last day of follow-up in uncorrected and PCR-corrected analysis. Posterior sampling was used to generate the PCR-corrected Kaplan–Meier estimates and 95% confidence intervals using the posterior probabilities of recrudescence.

Ethical considerations
The study was reviewed and approved by the institutional Ethics Committee of Biomedical Research of the Ministry of Public Health of Madagascar. The US CDC’s Center for Global Health Office of the Associate Director for Science determined CDC staff to be non-engaged in this research study (CDC human subjects 2016-012a). Local leaders and community members were informed of the study through meetings and radio broadcasts. Participants and parents were informed about the objectives of the project, benefits and risks associated with participation in the study; signed informed consent was obtained from parents before enrolment and children aged 7–14 years provided verbal assent.

Results
Study population
Of 1087 children in Ankazomborona and 663 Matanga who presented to the study site with fever, 561 and 365 were RDT-positive, respectively. Of these, 172 children, 86 in each treatment arm, met the study inclusion criteria and were enrolled at each study site. A total of 168 (83 for ASAQ and 85 for AL) and 167 (84 for ASAQ and 83 for AL) children reached the study endpoint in accordance with the study protocol in Ankazomborona and Matanga, respectively (Fig. 2). Demographic characteristics and parasite concentration of the enrolled children are reported in Table 1.
The uncorrected cumulative efficacy of ASAQ was 100% (95% CI 100–100) in Ankazomborona and 95% (95% CI 91–100) in Matanga. The PCR-corrected cumulative efficacy of ASAQ was 100% (95% CI 100–100) in Ankazomborona and 98% (95% CI 95–100) in Matanga (classification by genotyping can be found in Additional file 1: Table S1). In the ASAQ arm, one patient was parasitaemic on day-3 in Matanga and was classified as an early treatment failure. There were no late treatment failures observed in Ankazomborona. In Matanga, in addition to the early treatment failure, there was one late clinical failure, and three late parasitological failures in the ASAQ arm.

The uncorrected cumulative efficacy of AL was 99% (95% CI 97–100) in Ankazomborona and 83% (95% CI 76–92) in Matanga (classification by genotyping can be found in Additional file 1: Table S1). The PCR-corrected cumulative efficacy of AL was 100% (95% CI 99–100) in Ankazomborona and 95% (95% CI 91–100) in Matanga. In the AL arm, there were no patients with parasitaemia on day-3 in Ankazomborona. There was one child in the AL arm in the Matanga site who had 14 parasites per µl on day-3 which had cleared by day-7. There was one late clinical failure in Matanga.

### Table 1 Participants’ characteristics at enrollment, Ankazomborona and Matanga Districts, Madagascar, 2018 (n = 344)

|                | Ankazomborona         | Matanga          |
|----------------|-----------------------|------------------|
|                | ASAQ (n = 86)         | AL (n = 86)      | ASAQ (n = 86) | AL (n = 86) |
| Age (months), median (range) | 100 (19–180)         | 108 (18–178)     | 72 (8–180)    | 60 (8–180)    |
| Female, n (%)  | 37 (43)               | 31 (40)          | 41 (48)       | 42 (49)       |
| Weight (kg), mean, sd  | 21 (8)               | 21 (8)           | 18 (7)        | 18 (8)        |
| Baseline parasitemia, median parasites/µL (range) | 22,293 (1007–88,492) | 22,249 (1162–93,915) | 11,507 (1093–91,264) | 17,445 (1036–94,717) |
| Gametocytemia on day 0, n (%) | 3 (3)                | 3 (3)            | 4 (5)         | 2 (2)         |
| Reached Study end point, n (%) | 83 (97)              | 85 (99)          | 84 (98)       | 83 (97)       |

ASAQ artesunate-amodiaquine, AL artemether-lumefantrine, sd standard deviation

### Table 2 28-day uncorrected and PCR-corrected efficacy estimate, by drug, by site, Madagascar, 2018

|                | Ankazomborona         | Matanga          |
|----------------|-----------------------|------------------|
|                | ASAQ (n = 83)         | AL (n = 85)      | ASAQ (n = 84) | AL (n = 83) |
| Parasitemia day 2, n (%) | 1 (1)               | 14 (16)          | 8 (10)        | 9 (10)        |
| Parasitemia day 3, n (%) | 0                   | 0                | 1 (1)         | 1 (1)         |
| Early treatment failure, n (%) | 0                  | 0                | 0             | 0             |
| Late clinical failure, n (%) | 0                  | 1 (1)            | 1 (1)         | 2 (2)         |
| Late parasitological failure, n (%) | 0                  | 0                | 3 (4)         | 12 (14)c     |
| Recrudescence⁴ | 0                    | 0                | 2             | 2             |
| Day 14–21                  | 0                    | 0                | 1             | 0             |
| Day 22–28                  | 0                    | 0                | 1 (2)         | 2 (11)        |
| Reinfecction               | 0                    | 1                | 2             | 11            |
| Day 14–21                  | 0                    | 0                | 0             | 3             |
| Day 22–28                  | 0                    | 0                | 2 (8)         | 8             |
| Per protocol efficacy, n (%) [95% CI], uncorrected | 83 (100 [96–100]) | 84 (99 [94–100]) | 79 (94 [87–98]) | 69 (83 [73–90]) |
| Per protocol efficacy, n (%) [95% CI], PCR-corrected⁶ | 83 (100 [96–100]) | 84 (100 [96–100]) | 79 (97 [90–100]) | 69 (95 [87–99]) |
| Kaplan–Meier estimate of efficacy, uncorrected (%) [95% CI] | 100 (100–100) | 99 (97–100) | 95 (91–100) | 83 (76–92) |
| Kaplan–Meier estimate of efficacy, PCR-corrected (%) [95% CI]² | 100 (100–100) | 100 (99–100) | 98 (95–100) | 95 (91–100) |

ASAQ artesunate-amodiaquine, AL artemether-lumefantrine, CI confidence interval

⁴ Posterior probability of recrudescence ≥ 0.5
⁶ Posterior probability of recrudescence rather than whole numbers used for PCR-corrected estimates
² One late treatment failure had an indeterminate PCR
clinical failure in the Ankazomborona AL arm. There were two (2%) late clinical failures and 12 (14%) late parasitological failures in Matanga in the AL arm (see Table 2).

**Molecular markers of resistance**

A total of 85 day-0 and 18 day-of-recurrent-parasitaemia samples were assessed for presence of SNPs in *pfk13*, *pfmdr1* and *pfcrt*. Of these, 83/85 (98%) day-0 and 14/18 (78%) day of recurrent parasitaemia samples were successfully sequenced for *pfk13* and were all found to be wild type at the investigated codons (Table 3). For *pfmdr1*, mutations were found only in codons 86, 184 and 1246 (Tables 3 and 4). All samples were wild type for 1034 and 1042. *pfmdr1* haplotypes were constructed using codons N86Y, Y184F and D1246Y. There were 74/85 (87%) day-0 and 14/18 (78%) day of recurrent parasitaemia samples successfully sequenced at these three codons. The NFD and NYD haplotypes were found in

| Table 3 | Prevalence of polymorphisms from pre-treatment samples observed during a therapeutic efficacy study in Madagascar, stratified by eventual outcome |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Overall N = 85  | ACPR N = 65     | ETF N = 1       | Recrudescence N = 4 | Reinfection N = 14 |
| *pfk13*        |                |                |                |                  |                  |
| Wild type (no mutations detected) | n = 83 (100%) | n = 65 (100%) | n = 1 (100%) | n = 3 (100%) | n = 14 (100%) |
| *pfmdr1* N86Y |                |                |                |                  |                  |
| Successfully amplified | n = 81 (79%)   | n = 62 (78%)   | n = 1 (100%) | n = 4 (75%) | n = 14 (86%) |
| N               | 64 (79%)       | 48 (78%)       | 1 (100%)      | 3 (75%)       | 12 (64%)        |
| N/Y             | 2 (3%)         | 2 (3%)         | 0 (0%)        | 0 (0%)        | 0 (0%)          |
| Y               | 15 (19%)       | 12 (19%)       | 0 (0%)        | 1 (25%)      | 2 (14%)         |
| Y184F           |                |                |                |                  |                  |
| Successfully amplified | n = 82 (41%)  | n = 63 (36%)  | n = 1 (100%) | n = 4 (25%)  | n = 14 (79%) |
| Y               | 34 (41%)       | 23 (36%)       | 1 (100%)      | 1 (25%)      | 9 (64%)        |
| Y/F             | 7 (9%)         | 6 (10%)        | 0 (0%)        | 0 (0%)        | 1 (7%)          |
| F               | 41 (50%)       | 34 (54%)       | 0 (0%)        | 3 (75%)      | 4 (29%)        |
| S1034C          |                |                |                |                  |                  |
| Successfully amplified | n = 77 (100%) | n = 59 (100%) | n = 1 (100%) | n = 4 (100%) | n = 13 (100%) |
| S               | 77 (100%)      | 59 (100%)      | 1 (100%)      | 4 (100%)     | 13 (100%)      |
| N1042D          |                |                |                |                  |                  |
| Successfully amplified | n = 77 (100%) | n = 59 (100%) | n = 1 (100%) | n = 4 (100%) | n = 13 (100%) |
| N               | 77 (100%)      | 59 (100%)      | 1 (100%)      | 4 (100%)     | 13 (100%)      |
| D1246Y          |                |                |                |                  |                  |
| Successfully amplified | n = 77 (95%)  | n = 59 (97%)  | n = 1 (100%) | n = 4 (75%)  | n = 13 (92%) |
| D               | 73 (95%)       | 57 (97%)       | 1 (100%)      | 3 (75%)      | 12 (92%)       |
| D/Y             | 0 (0%)         | 0 (0%)         | 0 (0%)        | 0 (0%)       | 0 (0%)         |
| Y               | 4 (5%)         | 2 (3%)         | 0 (0%)        | 1 (25%)      | 1 (8%)         |
| *pfmdr1* haplotypes |                |                |                |                  |                  |
| Amplified for all 3 codons (86, 184, 1246) | n = 74 (50%)  | n = 56 (50%)  | n = 1 (100%) | n = 4 (100%) | n = 13 (100%) |
| NFD             | 37 (50%)       | 28 (50%)       | 1 (100%)      | 3 (75%)      | 5 (27%)        |
| NJY             | 30 (41%)       | 23 (41%)       | 0 (0%)        | 0 (0%)       | 1 (5%)         |
| YFD             | 6 (8%)         | 5 (9%)         | 0 (0%)        | 1 (25%)      | 0 (0%)         |
| YYD             | 8 (11%)        | 6 (11%)        | 0 (0%)        | 0 (0%)       | 2 (11%)        |
| YYY             | 1 (1%)         | 0 (0%)         | 0 (0%)        | 0 (0%)       | 1 (5%)         |
| YFY             | 1 (1%)         | 1 (1%)         | 0 (0%)        | 0 (0%)       | 0 (0%)         |
| NFY             | 2 (3%)         | 1 (1%)         | 0 (0%)        | 0 (0%)       | 1 (5%)         |
| *pfcrt* haplotypes |                |                |                |                  |                  |
| Amplified for all 5 codons (72—76) | n = 82 (100%) | n = 63 (100%) | n = 1 (100%) | n = 4 (100%) | n = 14 (100%) |
| CVMNK           | 82 (100%)      | 63 (100%)      | 1 (100%)      | 4 (100%)     | 14 (100%)      |

ACPR adequate clinical and parasitological response, ETF early treatment failure

a Investigated SNPs: F446I, N456Y, M476I, Y493H, R539T, I543T, P553L, R561H, C580Y

b mixed infections included in the numerator for each haplotype; therefore, column totals may sum to > 100%
For *pfcrt* codons 72–76, no mutations were found in the 82/85 day-0 (95%) and 13/18 (72%) day of recurrent parasitaemia samples that were successfully amplified.

**Discussion**

Both ASAQ and AL remain efficacious for the treatment of uncomplicated falciparum malaria among children in Matanga and Ankazomborona, Madagascar. For both medications, day-28 PCR-corrected efficacy exceeded the 90% threshold below which WHO recommends considering a change in first-line anti-malarials [8]. The findings in the ASAQ arm were consistent with those from the NMCP’s 2012–2016 therapeutic efficacy trials of ASAQ for uncomplicated malaria among individuals of all ages in six sites in Madagascar, including Matanga [9]. Results from that trial, which also followed the WHO protocol, revealed uncorrected and PCR-corrected efficacies above 90% for all six sites. For AL, however, no published studies of efficacy have been performed in Madagascar; thus, the current study serves as a baseline for the country. Of note, the efficacy findings of this study are consistent with ASAQ and AL therapeutic studies conducted in Mozambique, Madagascar’s closest neighbour on the African continent [25, 26].

The Matanga site had a higher rate of re-infection, which could be related to higher transmission intensity there, although in 2016 parasite prevalence among children 6–59 months was estimated at 9% in the zones where Matanga and Ankazomborona are located [18]. Routine health data from 2018 from districts encompassing these two communes suggested significantly higher disease rates among children two months to 14 years of age in Matanga compared with Ankazomborona (163

### Table 4 Prevalence of *pfmdr1* polymorphisms in pre-treatment and post-treatment samples stratified by site and treatment arms

|                | Pre-treatment | Post-treatment |
|----------------|---------------|----------------|
|                | AL            | ASAQ           | AL            | ASAQ           | AL            | ASAQ           |
|                | n (%)         | n (%)          | n (%)         | n (%)          | n (%)         | n (%)          |
| N = 15         | N = 16        | N = 1          | N = 0         | N = 29         | N = 21        | N = 10         | N = 3         |
| N86            |               |                |               |               |
| 10 (67)        | 12 (75)       | 1 (100)        | 0 (0)         | 26 (90)        | 16 (76)       | 9 (90)         | 3 (100)       |
| 86 N/Y         |               |                |               |               |
| 0 (0)          | 0 (0)         | 0 (0)          | 0 (0)         | 0 (0)          | 2 (10)        | 0 (0)          | 0 (0)         |
| 86Y            |               |                |               |               |
| 5 (33)         | 4 (25)        | 0 (0)          | 0 (0)         | 3 (10)         | 3 (14)        | 1 (10)         | 0 (0)         |

|                | N = 16        | N = 1          | N = 0         | N = 29         | N = 21        | N = 10         | N = 3         |
| Y184           | 2 (12)        | 10 (63)        | 1 (100)       | 0 (0)          | 15 (52)       | 7 (33)         | 5 (50)        | 2 (67)        |
| 184Y/F         | 0 (0)         | 1 (6)          | 0 (0)         | 0 (0)          | 3 (10)        | 3 (14)         | 0 (0)         | 0 (0)         |
| 184F           | 14 (88)       | 5 (31)         | 0 (0)         | 0 (0)          | 11 (38)       | 11 (52)        | 5 (50)        | 1 (33)        |

|                | N = 15        | N = 15         | N = 1         | N = 0         | N = 28        | N = 19         | N = 10        | N = 4         |
| D1246          | 13 (87)       | 14 (93)        | 1 (100)       | 0 (0)         | 28 (100)      | 18 (95)        | 10 (100)      | 4 (100)       |
| 1246D/Y        | 0 (0)         | 0 (0)          | 0 (0)         | 0 (0)         | 0 (0)         | 0 (0)          | 0 (0)         | 0 (0)         |
| 1246Y          | 2 (13)        | 1 (7)          | 0 (0)         | 0 (0)         | 0 (0)         | 1 (5)          | 0 (0)         | 0 (0)         |

|                | N = 15        | N = 14         | N = 1         | N = 0         | N = 27        | N = 18         | N = 10        | N = 3         |
| NYD            | 0 (0)         | 8 (57)         | 1 (100)       | 0 (0)         | 15 (50)       | 7 (39)         | 5 (50)        | 2 (67)        |
| YFD            | 2 (13)        | 1 (7)          | 0 (0)         | 0 (0)         | 0 (0)         | 3 (17)         | 1 (10)        | 0 (0)         |
| NFD            | 10 (67)       | 4 (29)         | 0 (0)         | 0 (0)         | 12 (44)       | 11 (61)        | 4 (40)        | 1 (33)        |
| NFY            | 0 (0)         | 1 (7)          | 0 (0)         | 0 (0)         | 0 (0)         | 1 (6)          | 0 (0)         | 0 (0)         |
| NYY            | 0 (0)         | 0 (0)          | 0 (0)         | 0 (0)         | 0 (0)         | 0 (0)          | 0 (0)         | 0 (0)         |
| YYD            | 1 (7)         | 1 (7)          | 0 (0)         | 0 (0)         | 3 (11)        | 3 (17)         | 0 (0)         | 0 (0)         |
| YFY            | 1 (7)         | 0 (0)          | 0 (0)         | 0 (0)         | 0 (0)         | 0 (0)          | 0 (0)         | 0 (0)         |
| YYY            | 1 (7)         | 0 (0)          | 0 (0)         | 0 (0)         | 0 (0)         | 0 (0)          | 0 (0)         | 0 (0)         |

† Each possible haplotype constructed from the mixed infections (wildtype and mutant) is reported; therefore, column totals may sum to > 100%
and 124 per 1000, respectively). In addition to differences between sites, the uncorrected efficacy of AL was lower than that of ASAQ. The shorter half-life of AL compared with ASAQ could indicate a shorter period of post-treatment prophylaxis resulting in higher numbers of re-infections in the AL arms [27, 28]. Additionally, AL absorption may have been compromised in this study because it was not administered with fatty food as recommended by the manufacturer [29]; however, drug levels were not collected, making this assertion impossible to ascertain. Evidence of sub-optimal efficacy of AL has been described in some African countries [10, 11, 30, 31]; reinforcement of correct AL administration (i.e., with fatty food) and close monitoring of efficacy for uncomplicated malaria are warranted in Madagascar.

No pfk13 mutations associated with artemisinin partial resistance were observed, suggesting continued susceptibility to artemisinin. This is consistent with clinical outcome data, which showed that by day-2, 156/165 (95%) participants in the ASAQ arm and 147/170 (86%) in the AL arm were aparasitaemic and by day-3, all but two participants were aparasitaemic. However, the recent identification of parasites in Rwanda harbouring a pfk13 mutation, R561H, with associated delayed clearance after treatment with AL underscores the importance of continued monitoring for pfk13 mutations in African TESs [7].

Mutations in the pfmdr1 gene have been shown to play a significant role in parasites’ tolerance to some anti-malarials such as chloroquine, amodiaquine, artemisinin derivatives, and lumefantrine; N86 wild type allele is implicated in decreased sensitivity to lumefantrine while the 86Y mutant allele, in combination with mutations in the pfcr gene, is associated with decreased sensitivity to chloroquine and amodiaquine [16, 32, 33]. pfmdr1 results in this study revealed a high prevalence of the N86 allele (NFD and NYD haplotypes), a finding seen recently in other countries throughout Southern and East Africa [7, 12, 34]. In six sites in Madagascar in 2006, the NFD and NYD haplotypes were observed in only 21.8 and 8.0% samples, respectively, although these frequencies increased to 30.0 and 14.6% just one year later [35]. With 82% of samples in two Madagascar sites containing the N86 allele in this 2018 study, this SNP’s (and associated haplotypes, NFD and NYD) prevalence appears to have increased further, although direct site-to-site comparison is not possible.

No mutations were observed in the 72–76 codons of the pfcr gene, which is consistent with several studies conducted in Madagascar [35, 36]. Mutations in this gene, especially the 76 T codon, were associated with resistance to chloroquine and amodiaquine in several African countries which then reported the “return” of chloroquine-susceptible parasites with wild type alleles, as early as 10 years after chloroquine withdrawal [37, 38]. Madagascar is among countries not recommending the use of chloroquine for treatment of malaria in over 10 years due to high rates of chloroquine treatment failures. In contrast to what was observed in other African countries, chloroquine treatment failures in Madagascar were observed in the absence of pfcr mutations but were significantly associated with the pfmdr1 86Y mutant allele [35, 36, 39]. This study is similar to these previous studies, which reported the absence or very low prevalence of pfcr mutations in Madagascar.

Conclusion
First- and second-line ACT remain efficacious for uncomplicated falciparum malaria in Madagascar; however, periodic monitoring to ensure anti-malarial drug efficacy and the continued absence of worrisome mutations is essential.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12936-021-03935-4.

Acknowledgements
The authors would like to acknowledge Omega Raobela, Malalanandrianina A. Rakotoarisoa, Tojoniaina H. Ramandimbisoa, Claude L. Jaona Rahajarimannirina, Ahmed M. Marolahy, Maminirina S. Rabearimanana, Fanomezantsoa Ralimo, Brunette Ranantadrazanina, Noeline Rascoaiala, Tiavina M. Rakotomanjaka, Hasinirina R. Raherinafajy and the Institut Pasteur de Madagascar.

Authors’ contributions
CMD, TAR, MAR, LCS, ESH, and AR developed the initial protocol. TAR, MAR, ANR, and AR trained and supervised the data collection teams and finalized the survey tools. TAR, SSS and NWL performed the molecular laboratory assays. CMD, TAR, LCS, LFM, SSS, NWL performed data management, cleaning, and analysis. CMD, TAR, LCS, LFM, SSS, NWL, and ESH wrote and edited the manuscript. All authors read and approve the final manuscript.

Funding
Funding for this assessment was obtained from the United States President’s Malaria Initiative (PMI) via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, US Agency for International Development. The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of any collaborating institute including the Centers for Disease Control and Prevention nor the US Agency for International Development. Staff from PMI were involved in the development of the protocol, survey tools, survey implementation, data analysis, and manuscript preparation.

Availability of data and materials
The datasets generated and/or analysed during the current study have been de-identified and uploaded to USAID’s data development library (DDL).
Declarations

Ethics approval and consent to participate
Ethics approval and consent was obtained from the Institutional Ethics Committee of the Ministry of Public Health of Madagascar. This assessment was approved as a non-research programme evaluation activity by the Office of the Associate Director of Science, Center for Global Health, US CDC, Atlanta GA.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, US Centers for Disease Control and Prevention, Antananarivo, Madagascar. 2. University of Antananarivo, Antananarivo, Madagascar. 
3. University of Antananarivo, Antananarivo, Madagascar. 4. University of Antananarivo, Antananarivo, Madagascar.

References
1. Institut National de la Statistique, Cellule Centrale d’Exécution du Recensement. Résultats Provissiers du Troisicème Recensement Général de la Population et de l’Habitation. Antananarivo, Madagascar. 2019.
2. Ministère de la Santé Publique, Programme National de Lutte Contre le Paludisme. Routine data. Antananarivo, Madagascar. 2020.
3. Ministère de la Santé Publique, Secrétariat Général. Plan stratégique national de lutte contre le paludisme, Madagascar, 2018–2022. Antanananivo. 2017.
4. Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, et al. Efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11:1800–7.
5. Phyo AP, Nikhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artesiminin-resistant resistant to the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
6. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Arte- misinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
7. Uwimana A, Umulisa N, Venkatesan M, Sigiel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120–8.
8. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009.
9. Pradonqela O, Andriantsoaninina V, Rajaonaerana DG, Pakiotomanga TA, Rabeairaminana S, Ranorino F. Efficacy of artesunate–amodiaquine in the treatment of falciparum uncomplicated malaria in Madagascar. Malar J. 2018;17:284.
10. Plucinski MM, Dimbu PR, Macaia AP, Ferreira CM, Samutondoa C, Quivinha J, et al. Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola. 2015. Malar J. 2017;16:622.
11. Gansane A, Moriaty LF, Ménard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy and resistance monitoring of artemether–lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018. Malar J. 2021;20:48.
12. Dimbu PR, Horth R, Cândido ALM, Ferreira CM, Caquece F, Garcia LEA, et al. Continued low efficacy of artether-lumefantrine in Angola, 2019. Antimicrob Agents Chemother. 2021;65:e-1949-20.
13. Strauss J, Gräfner NF, Witkowski B, Amarutanga C, Duru V, Ramadanii AP, et al. K13-propeller mutations confer artemisinin resistance in Plasmo- dium falciparum clinical isolates. Science. 2015;347:428–31.
14. Ecker A, Lehane AM, Clay J, Fidock DA. PCRT and its role in antimalarial drug resistance. Trends Parasitol. 2011;27:504–14.
15. Maimberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842–7.
16. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P.falciparum malaria after artether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43.
17. Price RN, Uhlemann A-C, van Vugt M, Brockman A, Hutafulungu R, Nair S, et al. Molecular and pharmacological determinants of the therapeutic response to artether–lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006;42:1570–7.
18. Institut National de la Statistique—INSTAT/Madagascar, Programme National de lutte contre le Paludisme—PNLP/Madagascar, Institut Pasteur de Madagascar—IPM/Madagascar, and ICF International. Enquête sur les Indicateurs du Paludisme 2016. Calverton, MD, USA : INSTAT, PNLP, IPM and ICF International, 2016.
19. Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity development through the US President’s malaria initiative-supported antimalarial resistance monitoring in africa network. Emerg Infect Dis. 2017;23:533-56.
20. Talundzic E, Chenet SM, Goldman IF, Patel NS, Nelson JA, Plucinski MM, et al. Genetic analysis and species specific amplification of the artemisinin resistance-associated kelch propeller domain in P. falciparum and P. vivax. PLoS ONE. 2015;10: e0136099.
21. Greenhouse B, Myrick A, Dokomajilar C, Wuo J, Carlson EJ, Rosenthal PJ, et al. Validation of microsatellite markers for use in genotyping polymodal Plasmodium falciparum infections. Am J Trop Med Hyg. 2006;75:836–42.
22. Anderson TJC, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol. 2000;17:1467–62.
23. Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V; Robust algorithm for systematic classification of malaria late treatment failures as recrudescence or reinfection using microsatellite genotyping. Antimicrob Agents Chemother. 2015;59:6096–100.
24. WHO. Tools for monitoring antimalarial drug efficacy. Geneva: World Health Organization. 2020. http://www.who.int/malaria/areas/drug_resis- tance/efficacy-monitoring-tools/en/. Accessed 13 Jun 2020.
25. Salvador C, Rafael B, Matsuhe F, Buthemba R, De Carvalho E, et al. Efficacy and safety of artether–lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015. Acta Trop. 2017;171:146–50.
26. Nhamu A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E, et al. Polymorphisms in Plasmodium falciparum and Plasmodium vivax drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis. 2013;207:842–7.
27. Talundzic E, Chenet SM, Goldman IF, Patel NS, Nelson JA, Plucinski MM, et al. Genetic analysis and species specific amplification of the artemisinin resistance-associated kelch propeller domain in P. falciparum and P. vivax. PLoS ONE. 2015;10: e0136099.
uncomplicated *Plasmodium falciparum* malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.

31. Abuaku B, Duah N, Quaye L, Quashie N, Malm K, Bart-Plange C, et al. Therapeutic efficacy of artesunate–amodiaquine and artemether–lumefantrine combinations in the treatment of uncomplicated malaria in two ecological zones in Ghana. Malar J. 2016;15:6.

32. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop. 2005;94:181–90.

33. Bygbjerg IC, Alifrangis M, Tomás EVE, Charlwood D, Thomsen TT, Madsen LB, et al. Rapid selection of *Plasmodium falciparum* chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, Southern Mozambique. Am J Trop Med Hyg. 2013;88:536–41.

34. Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of PfK13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.

35. Andriantsoanirina V, Ratsimbosoa A, Bouchier C, Jahevitra M, Rabearimanana S, et al. *Plasmodium falciparum* drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob Agents Chemother. 2009;53:4588–97.

36. Andriantsoanirina V, Ratsimbosoa A, Bouchier C, Tichit M, Jahevitra M, Rabearimanana S, et al. Chloroquine clinical failures in *P. falciparum* malaria are associated with mutant pfmdr-1, not pfcr in Madagascar. PLoS ONE. 2010;5:e13281.

37. Laufer MK, Dzinjalamala FK. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959–66.

38. Mharakurwa S, Matsena-Zingoni Z, Mudeae N, Matimba C, Gara TX, Makuwaza A, et al. Steep rebound of chloroquine-sensitive *Plasmodium falciparum* in Zimbabwe. J Infect Dis. 2021;223:306–9.

39. Rason M-A, Andrianantenaina HB, Domaarle O, Anesy F, Randrianarivelosia M, Raveloson A. Prevalent Pfmdr1 N86y mutant *Plasmodium falciparum* in Madagascar despite absence of Pfcrf mutant strains. Am J Trop Med Hyg. 2007;76:1079–83.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.